-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – S-65487 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-65487 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-65487 in Marginal Zone B-cell Lymphoma Drug Details: S-65487...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – S-65487 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-65487 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-65487 in Diffuse Large B-Cell Lymphoma Drug Details: S-65487...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Maveropepimut-s in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maveropepimut-s in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maveropepimut-s in Diffuse Large B-Cell Lymphoma Drug Details: Maveropepimut-s (DPX-Survivac)...
-
Company Insights
Innovation and Patenting activity of B&S Group SA Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of B&S Group SA Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – S-65487 in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. S-65487 in Diffuse Large B-Cell Lymphoma Drug Details: S-65487 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – S-65487 in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. S-65487 in Marginal Zone B-cell Lymphoma Drug Details: S-65487 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – S-055746 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-055746 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-055746 in B-Cell Non-Hodgkin Lymphoma Drug Details: S-055746 is under...
-
Analyst Opinions
NewFactors of Influence for Purchases – Key Trends and Consumer Insights
Understand the key factors influencing global consumers’ purchasing decisions across different sectors and countries, and case studies of different retailer types that benefit from different consumer priorities. The top five factors that influence consumers’ purchasing choices are value for money, quality, price, discounts and promotions, and range. Amidst economic uncertainty, geopolitical tensions, and persistent inflation, consumer sentiment remains negative across major economies, leading to a continued focus on price. The impact of social media on purchasing decisions varies widely; it...
-
Sector Analysis
Inferior Vena Cava Filters (IVCF) Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Inferior Vena Cava Filters (IVCF) Market Report Overview The inferior vena cava filters (IVCF) market was valued at $128 million in 2023 and will decline at a CAGR of more than 1% during 2023-2033. IVCF is a metallic device used to prevent blood clots from traveling to the lungs. The filter is inserted inside a large vein called the inferior vena cava (IVC). IVC filter traps blood clots before they reach the lungs. IVCF Market Outlook 2023-2033 ($ Million) For...